Aggressive melanoma cells escape from BMP7-mediated autocrine growth inhibition through coordinated Noggin upregulation

Laboratory Investigation

Volumn 88, Issue 8, 2008, Pages 842-855

  Hsu, Mei Yu ^a,b   Rovinsky, Sherry A ^b   Lai, Chiou Yan ^a   Qasem, Shadi ^b   Liu, Xiaoming ^b   How, Joan ^a   Engelhardt, John F ^b   Murphy, George F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Adenoviral gene transfer; BMP antagonist; BMP inhibitor; Skin reconstruct; TGF ; Tumor progression

Indexed keywords

ADENOVIRUS VECTOR; LENTIVIRUS VECTOR; NOGGIN; OSTEOGENIC PROTEIN 1; SHORT HAIRPIN RNA;

ANCHORAGE DEPENDENT GROWTH; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CANCER INHIBITION; CELL GROWTH; CELL PROTECTION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; SCID MOUSE; UPREGULATION;

ADENOVIRIDAE; AUTOCRINE COMMUNICATION; BONE MORPHOGENETIC PROTEINS; CARRIER PROTEINS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GROWTH INHIBITORS; HUMANS; MELANOCYTES; MELANOMA; NEOPLASM INVASIVENESS; TRANSDUCTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 48749131979     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.55     Document Type: Article

References (57)

1. Balemans W, Van Hul W. Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev Biol 2002;250:231-250.
2. Whitman M. Smads and early developmental signaling by the TGFbeta superfamily. Genes Dev 1998;12:2445-2462.
3. Botchkarev VA. Bone morphogenetic proteins and their antagonists in skin and hair follicle biology. J Invest Dermatol 2003;120:36-47.
4. Hsu MY, Rovinsky S, Penmatcha S, et al. Bone morphogenetic proteins in melanoma: angel or devil? Cancer Metastasis Rev 2005;24:251-263.
5. Howe JR, Sayed MG, Ahmed AF, et al. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J Med Genet 2004;41:484-491.
6. Waite KA, Eng C. From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family. Nat Rev Genet 2003;4:763-773.
7. Langenfeld EM, Calvano SE, Abou-Nukta F, et al. The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 2003;24:1445-1454.
8. Kim IY, Lee DH, Lee DK, et al. Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1. Cancer Res 2004;64:7355-7360.
9. Horvath LG, Henshall SM, Kench JG, et al. Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate 2004;59:234-242.
10. Wen XZ, Miyake S, Akiyama Y, et al. BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. Biochem Biophys Res Commun 2004;316:100-106.
11. Helms MW, Packeisen J, August C, et al. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. J Pathol 2005;206:366-376.
12. Rothhammer T, Poser I, Soncin F, et al. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 2005;65:448-456.
13. Rothhammer T, Wild PJ, Meyer S, et al. Bone morphogenetic protein 7 (BMP7) expression is a potential noval prognostic marker for recurrence in patients with primary melanoma. Cancer Biomarker 2007;3:111-117.
14. Hsu M-Y, Li L, Herlyn M. Cultivation of normal human epidermal melanocytes in the absence of phorbol esters. In: Picot J (ed). Human Cell Culture Protocols. Humana Press: Totowa, NJ, 2004, pp 13-28.
15. Hsu M-Y, Elder DE, Herlyn M. Melanoma: the Wistar melanoma (WM) cell lines. In: Masters JRW, Palsson B (eds). Human Cell Culture, 1st edn. Kluwer Academic Publishers: Nowell, MA, 1999, pp 259-274.
16. van der Schaft DW, Seftor RE, Seftor EA, et al. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 2004;96:1473-1477.
17. Hsu MY, Shih DT, Meier FE, et al. Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol 1998;153:1435-1442.
18. Hsu MY, Meier FE, Nesbit M, et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and downregulates expression of invasion-related adhesion receptors. Am J Pathol 2000;156:1515-1525.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408.
20. Franceschi RT, Wang D, Krebsbach PH, et al. Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7. J Cell Biochem 2000;78:476-486.
21. Smith WC, Harland RM. Expression cloning of noggin, a new dorsalizing factor localized to the Spemann organizer in Xenopus embryos. Cell 1992;70:829-840.
22. Zimmerman LB, De Jesus-Escobar JM, Harland RM. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 1996;86:599-606.
23. Anderson RD, Haskell RE, Xia H, et al. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Therapy 2000;7:1034-1038.
24. Hsu M, Andl T, Li G, et al. Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci 2000;113:1535-1542.
25. Valenzuela DM, Economides AN, Rojas E, et al. Identification of mammalian noggin and its expression in the adult nervous system. J Neurosci 1995;15:6077-6084.
26. Marcelino J, Sciortino CM, Romero MF, et al. Human disease-causing NOG missense mutations: effects on noggin secretion, dimer formation, and bone morphogenetic protein binding. Proc Natl Acad Sci USA 2001;98:11353-11358.
27. Meier F, Nesbit M, Hsu MY, et al. Human melanoma progression in skin reconstructs: biological significance of bFGF. Am J Pathol 2000;156:193-200.
28. Wang SN, Lapage J, Hirschberg R. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 2001;12:2392-2399.
29. Scherberich A, Tucker RP, Degen M, et al. Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro. Oncogene 2005;24:1525-1532.
30. Ye L, Lewis-Russell JM, Kynaston H, et al. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists. J Urol 2007;178:1086-1091.
31. Grijelmo C, Rodrigue C, Svrcek M, et al. Proinvasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells. Cell Signal 2007;19:1722-1732.
32. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001;411:349-354.
33. Masuda H, Fukabori Y, Nakano K, et al. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 2003;54:268-274.
34. Alarmo EL, Rauta J, Kauraniemi P, et al. Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer. Genes Chromosomes Cancer 2006;45:411-419.
35. Higinbotham KG, Karavanova ID, Diwan BA, et al. Deficient expression of mRNA for the putative inductive factor bone morphogenetic protein-7 in chemically initiated rat nephroblastomas. Mol Carcinog 1998;23:53-61.
36. Ro TB, Holt RU, Brenne AT, et al. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 2004;23:3024-3032.
37. Midorikawa Y, Ishikawa S, Iwanari H, et al. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 2003;103:455-465.
38. Pouliot F, Blais A, Labrie C. Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. Cancer Res 2003;63:277-281.
39. Valtieri M, Tocci A, Gabbianelli M, et al. Enforced TAL-1 expression stimulates primitive, erythroid and megakaryocytic progenitors but blocks the granulopoeitic differentiation program. Cancer Res 1998;58:562-569.
40. Miyazaki H, Watabe T, Kitamura T, et al. BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene 2004;23:9326-9335.
41. Yang S, Zhong C, Frenkel B, et al. Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res 2005;65:5769-5777.
42. Ide H, Yoshida T, Matsumoto N, et al. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 1997;57:5022-5027.
43. Langenfeld EM, Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res 2004;2:141-149.
44. Moll F, Millet C, Noel D, et al. Chordin is underexpressed in ovarian tumors and reduces tumor cell motility. FASEB J 2006;20:240-250.
45. Fukuchi M, Fukai Y, Masuda N, et al. High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Res 2002;62:7162-7165.
46. Xiang YY, Ladeda V, Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene 2001;20:7408-7412.
47. Lin H, Huber R, Schlessinger D, et al. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 1999;59:807-810.
48. Saikali Z, Sinnett D. Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer 2000;89:418-422.
49. Lage H, Dietel M, Froschle G, et al. Expression of the novel mitoxantrone resistance associated gene MXR7 in colorectal malignancies. Int J Clin Pharmacol Ther 1998;36:58-60.
50. Man XB, Tang L, Zhang BH, et al. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Liver Int 2005;25:962-966.
51. Nakatsura T, Kageshita T, Ito S, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004;10:6612-6621.
52. Motomura Y, Senju S, Nakatsura T, et al. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Cancer Res 2006;66:2414-2422.
53. Kraunz KS, Nelson HH, Liu M, et al. Interaction between the bone morphogenetic proteins and Ras/MAP-kinase signalling pathways in lung cancer. Br J Cancer 2005;93:949-952.
54. Nakashima A, Katagiri T, Tamura M. Cross-talk between Wnt and bone morphogenetic protein 2 (BMP-2) signaling in differentiation pathway of C2C12 myoblasts. J Biol Chem 2005;280:37660-37668.
55. Litsiou A, Hanson S, Streit A. A balance of FGF, BMP and WNT signalling positions the future placode territory in the head. Development 2005;132:4051-4062.
56. Dai J, Kitagawa Y, Zhang J, et al. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 2004;64:994-999.
57. Raida M, Clement JH, Leek RD, et al. Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. J Cancer Res Clin Oncol 2005;131:741-750.